Featured Research

from universities, journals, and other organizations

New Vaccine Technique Offers Hope For Asthma And Allergy Sufferers

Date:
April 7, 2000
Source:
Johns Hopkins Medical Institutions
Summary:
For years, efforts to develop improved vaccines for asthma and allergies have been thwarted because the vaccines themselves often cause the very symptoms a person is trying to avoid. Research efforts have been aimed at attempting to improve efficacy, increase safety, decrease treatment time and improve compliance. Now, at a recent conference, researchers at Johns Hopkins, the University of California at San Diego, and Dynavax Technologies Corporation announce that they have developed a method of modifying an allergen, such as ragweed, to create a vaccine that may solve many of these concerns.

For years, efforts to develop improved vaccines for asthma and allergies have been thwarted because the vaccines themselves often cause the very symptoms a person is trying to avoid. Research efforts have been aimed at attempting to improve efficacy, increase safety, decrease treatment time and improve compliance. Now, at a recent conference, researchers at Johns Hopkins, the University of California at San Diego, and Dynavax Technologies Corporation announce that they have developed a method of modifying an allergen, such as ragweed, to create a vaccine that may solve many of these concerns.

"Our first experience of testing this new vaccine approach in ragweed-allergic people supports the hypothesis that this novel vaccine may provide a safer and potentially more effective therapeutic vaccine for allergic diseases," says Peter S. Creticos, M.D., an associate professor of medicine at Johns Hopkins.

Creticos reports the new research at the 15th Annual Update of Frontiers in Research and Clinical Management of Asthma and Allergy held March 31 through April 2 in Baltimore.

People suffer allergic reactions when their immune systems overreact to an allergen such as ragweed pollen. The allergen typically induces certain immune cells, including the type 2 helper T cells (Th2), to produce a variety of biochemicals responsible for the allergy sufferers' miseries.

To combat these reactions, doctors traditionally have injected an individual with a vaccine containing the allergen that is causing them trouble. Injecting an allergen apparently causes the body to produce less Th2 than what would occur if a person were to encounter the allergen naturally. These vaccines cause the body to produce allergen-attacking antibodies. Through a series of these vaccinations, which to the body are like handicapped fights, the immune system learns how to defend itself and becomes a better fighter when the real agent attacks. Some vaccines, however, cannot be tolerated by individuals because the antigen in the vaccine is so strong that, even when injected, it elicits a potent allergic reaction.

To create a more tolerable vaccine, the researchers realized that they must "mask" the allergic sites on the allergen molecule. They discovered that this could be accomplished by attaching a specific, short sequence of synthetic DNA to the relevant allergen. Researchers have shown that this DNA sequence can induce the body to produce protective molecules, type 1 helper T cells (Th1). Th1 cells inhibit the pro-inflammatory Th2 cells responsible for the allergic inflammatory reaction.

"In animal studies and in laboratory tests with human cells, this approach has been shown to be very effective in terms of being able to generate immunity," says Lawrence Lichtenstein, M.D., Ph.D., a professor of clinical immunology at Johns Hopkins who is involved in the new research.

Now, Creticos reports the results of the first human studies with this novel modified vaccine, named AIC. In the new study, six ragweed-allergic volunteers underwent skin testing in a blinded fashion with both ragweed and AIC. Skin testing is a way of measuring redness and swelling to determine the allergic response produced by an allergen, in this case ragweed. The researchers found that the new AIC product was 180 times less allergenic than a licensed product. This preliminary clinical experiment confirms the results of the previous animal work and human blood test work. The researchers hope to begin phase I clinical efficacy trials in the near future.

The study was sponsored by Dynavax Technologies Corporation. Lichtenstein serves on Dynavax's Scientific Advisory Board and owns Dynavax stock, which is subject to certain restrictions under Johns Hopkins policy. Creticos is a scientific consultant to the company. The terms of this arrangement are being managed by the university in accordance with its conflict of interest policies.


Story Source:

The above story is based on materials provided by Johns Hopkins Medical Institutions. Note: Materials may be edited for content and length.


Cite This Page:

Johns Hopkins Medical Institutions. "New Vaccine Technique Offers Hope For Asthma And Allergy Sufferers." ScienceDaily. ScienceDaily, 7 April 2000. <www.sciencedaily.com/releases/2000/04/000406091203.htm>.
Johns Hopkins Medical Institutions. (2000, April 7). New Vaccine Technique Offers Hope For Asthma And Allergy Sufferers. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2000/04/000406091203.htm
Johns Hopkins Medical Institutions. "New Vaccine Technique Offers Hope For Asthma And Allergy Sufferers." ScienceDaily. www.sciencedaily.com/releases/2000/04/000406091203.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
US to Track Everyone Coming from Ebola Nations

US to Track Everyone Coming from Ebola Nations

AP (Oct. 22, 2014) Stepping up their vigilance against Ebola, federal authorities said Wednesday that everyone traveling into the US from Ebola-stricken nations will be monitored for symptoms for 21 days. (Oct. 22) Video provided by AP
Powered by NewsLook.com
Doctors Help Paralysed Man Walk Again, Patient in Disbelief

Doctors Help Paralysed Man Walk Again, Patient in Disbelief

AFP (Oct. 22, 2014) Polish doctors describe how they helped a paralysed man walk again, with the patient in disbelief at the return of sensation to his legs. Duration: 1:04 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins